New trial is launched to test Interleukin-2 for the treatment of motor neurone disease. Credit: Euan MacDonald Centre.

MND Scotland has launched a new clinical trial to test the safety and effectiveness of Interleukin-2, which is used for some types of cancer, as well as the treatment of Amyotrophic Lateral Sclerosis (ALS) or motor neurone disease (MND).

The trial, titled Modifying Immune Response and Outcomes in Amyotrophic Lateral Sclerosis (MIROCALS), is currently being conducted in the UK and France.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is enrolling patients in Glasgow, Scotland, with an aim to focus on the types of immune cells in the blood, which are capable of influencing the speed at which ALS progresses.

These immune cells, known as Regulatory T-Cells, are believed to play an important role in protecting the motor neurones.

Interleukin-2, which is naturally produced in the body, has the ability to increase the production of these special immune cells in the blood.

“This will be a tremendous help in reaching our recruitment target faster and thus being able to complete the whole study as soon as possible.”

MIROCALS chief trial investigator said: “This will be a tremendous help in reaching our recruitment target faster and thus being able to complete the whole study as soon as possible.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our main goal is to find a new treatment to slow down the progression of ALS, but this project will also deliver many new insights into the disease, and make a major contribution to improving future trials in ALS and other neurodegenerative disorders.”

Queen Elizabeth University Hospital consultant neurologist Dr George Gorrie will lead the trial in Scotland, which will receive parts of its funding from MND Scotland.

MND Scotland has previously made a commitment to provide more than £1.5m for MND drug trials in Scotland, with MIROCALS being their first investment.